186 related articles for article (PubMed ID: 35434578)
1. Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).
Hernández-Bernal F; Ricardo-Cobas MC; Martín-Bauta Y; Navarro-Rodríguez Z; Piñera-Martínez M; Quintana-Guerra J; Urrutia-Pérez K; Urrutia-Pérez K; Chávez-Chong CO; Azor-Hernández JL; Rodríguez-Reinoso JL; Lobaina-Lambert L; Colina-Ávila E; Bizet-Almeida J; Rodríguez-Nuviola J; Del Valle-Piñera S; Ramírez-Domínguez M; Tablada-Ferreiro E; Alonso-Valdés M; Lemos-Pérez G; Guillén-Nieto GE; Palenzuela-Díaz A; Noa-Romero E; Limonta-Fernández M; Fernández-Ávila JM; Ali-Mros NA; Del Toro-Lahera L; Remedios-Reyes R; Ayala-Ávila M; Muzio-González VL
EClinicalMedicine; 2022 Apr; 46():101383. PubMed ID: 35434578
[TBL] [Abstract][Full Text] [Related]
2. A phase 3, randomised, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 study).
Hernández-Bernal F; Ricardo-Cobas MC; Martín-Bauta Y; Rodríguez-Martínez E; Urrutia-Pérez K; Urrutia-Pérez K; Quintana-Guerra J; Navarro-Rodríguez Z; Piñera-Martínez M; Rodríguez-Reinoso JL; Chávez-Chong CO; Baladrón-Castrillo I; Melo-Suárez G; Batista-Izquierdo A; Pupo-Micó A; Mora-Betancourt R; Bizet-Almeida J; Martínez-Rodríguez MC; Lobaina-Lambert L; Velázquez-Pérez VM; Soler-Díaz J; Laurencio-Vallina S; Meriño-Hechavarría T; Carmenaty-Campos N; Rodríguez-Montero E; Limonta-Fernández M; Alonso-Valdés M; Hernández-Rodríguez R; Pimentel-Vázquez E; Catasús-Álvarez KM; Cabrera-Núñez MV; Ayala-Ávila M; Muzio-González VL;
Lancet Reg Health Am; 2023 May; 21():100497. PubMed ID: 37192953
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3-18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study).
Cinza-Estévez Z; Resik-Aguirre S; Figueroa-Baile NL; Oquendo-Martínez R; Campa-Legrá I; Tejeda-Fuentes A; Rivero-Caballero M; González-García G; Chávez-Chong CO; Alonso-Valdés M; Hernández-Bernal F; Lemos-Pérez G; Campal-Espinosa A; Freyre-Corrales G; Benítez-Gordillo D; Gato-Orozco E; Pérez Bartutis GS; Mesa-Pedroso I; Bueno-Alemani N; Infante-Aguilar E; Rodríguez Reinoso JL; Melo-Suarez G; Limonta-Fernández M; Ayala-Ávila M; Muzio-González VL;
EClinicalMedicine; 2023 Sep; 63():102160. PubMed ID: 37649806
[TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a protein subunit COVID-19 vaccine (ZF2001) in healthy children and adolescents aged 3-17 years in China: a randomised, double-blind, placebo-controlled, phase 1 trial and an open-label, non-randomised, non-inferiority, phase 2 trial.
Gao L; Li Y; He P; Chen Z; Yang H; Li F; Zhang S; Wang D; Wang G; Yang S; Gong L; Ding F; Ling M; Wang X; Ci L; Dai L; Gao GF; Huang T; Hu Z; Ying Z; Sun J; Zuo X
Lancet Child Adolesc Health; 2023 Apr; 7(4):269-279. PubMed ID: 36803632
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Yang S; Li Y; Dai L; Wang J; He P; Li C; Fang X; Wang C; Zhao X; Huang E; Wu C; Zhong Z; Wang F; Duan X; Tian S; Wu L; Liu Y; Luo Y; Chen Z; Li F; Li J; Yu X; Ren H; Liu L; Meng S; Yan J; Hu Z; Gao L; Gao GF
Lancet Infect Dis; 2021 Aug; 21(8):1107-1119. PubMed ID: 33773111
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS
Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults.
Jin Z; Wu J; Wang Y; Huang T; Zhao K; Liu J; Wang H; Zhu T; Gou J; Huang H; Wu X; Yin H; Song J; Li R; Zhang J; Li L; Chen J; Li X; Zhang M; Li J; Hou M; Song Y; Wang B; Gao Q; Wu L; Kong Y; Dong R
J Infect; 2023 Dec; 87(6):556-570. PubMed ID: 37898410
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial.
Ochoa-Azze R; Chang-Monteagudo A; Climent-Ruiz Y; Macías-Abraham C; Valenzuela-Silva C; de Los Ángeles García-García M; Jerez-Barceló Y; Triana-Marrero Y; Ruiz-Villegas L; Dairon Rodríguez-Prieto L; Guerra-Chaviano PP; Sánchez-Ramírez B; Hernández-García T; Orosa-Vázquez I; Díaz-Hernández M; Chiodo F; Calcagno A; Ghisetti V; Rodríguez-Acosta M; Noa-Romero E; Enríquez-Puertas J; Ortega-León D; Valdivia-Álvarez I; Delahanty-Fernández A; Palenzuela-Díaz A; Rodríguez-Noda L; González-Mugica R; Valdés-Balbín Y; García-Rivera D; Verez-Bencomo V
Lancet Respir Med; 2022 Aug; 10(8):785-795. PubMed ID: 35691295
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY
Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial.
Song JY; Choi WS; Heo JY; Lee JS; Jung DS; Kim SW; Park KH; Eom JS; Jeong SJ; Lee J; Kwon KT; Choi HJ; Sohn JW; Kim YK; Noh JY; Kim WJ; Roman F; Ceregido MA; Solmi F; Philippot A; Walls AC; Carter L; Veesler D; King NP; Kim H; Ryu JH; Lee SJ; Park YW; Park HK; Cheong HJ
EClinicalMedicine; 2022 Sep; 51():101569. PubMed ID: 35879941
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
Zhu FC; Guan XH; Li YH; Huang JY; Jiang T; Hou LH; Li JX; Yang BF; Wang L; Wang WJ; Wu SP; Wang Z; Wu XH; Xu JJ; Zhang Z; Jia SY; Wang BS; Hu Y; Liu JJ; Zhang J; Qian XA; Li Q; Pan HX; Jiang HD; Deng P; Gou JB; Wang XW; Wang XH; Chen W
Lancet; 2020 Aug; 396(10249):479-488. PubMed ID: 32702299
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
Pérez-Rodríguez S; de la Caridad Rodríguez-González M; Ochoa-Azze R; Climent-Ruiz Y; Alberto González-Delgado C; Paredes-Moreno B; Valenzuela-Silva C; Rodríguez-Noda L; Perez-Nicado R; González-Mugica R; Martínez-Pérez M; Sánchez-Ramírez B; Hernández-García T; Díaz-Machado A; Tamayo-Rodríguez M; Martín-Trujillo A; Rubino-Moreno J; Suárez-Batista A; Dubed-Echevarría M; Teresa Pérez-Guevara M; Amoroto-Roig M; Chappi-Estévez Y; Bergado-Báez G; Pi-Estopiñán F; Chen GW; Valdés-Balbín Y; García-Rivera D; Verez-Bencomo V
Vaccine; 2022 Mar; 40(13):2068-2075. PubMed ID: 35164986
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
[TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials.
Ozdarendeli A; Sezer Z; Pavel STI; Inal A; Yetiskin H; Kaplan B; Uygut MA; Bayram A; Mazicioglu M; Unuvar GK; Yuce ZT; Aydin G; Aslan AF; Kaya RK; Koc RC; Ates I; Kara A
Vaccine; 2023 Jan; 41(2):380-390. PubMed ID: 36460536
[TBL] [Abstract][Full Text] [Related]
18. An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, double-blind trial.
Pollock KM; Borges ÁH; Cheeseman HM; Rosenkrands I; Schmidt KL; Søndergaard RE; Day S; Evans A; McFarlane LR; Joypooranachandran J; Amini F; Skallerup P; Dohn RB; Jensen CG; Olsen AW; Bang P; Cole T; Schronce J; Lemm NM; Kristiansen MP; Andersen PL; Dietrich J; Shattock RJ; Follmann F
Lancet Infect Dis; 2024 Apr; ():. PubMed ID: 38615673
[TBL] [Abstract][Full Text] [Related]
19. Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial.
Kudriavtsev AV; Vakhrusheva AV; Kryuchkov NA; Frolova ME; Blagodatskikh KA; Ivanishin TV; Djonovic M; Romanovskaya-Romanko EA; Kovalenko AN; Lioznov DA; Zubkova TG; Teplykh SV; Oseshnyuk RA; Stukova MA; Isaev AA; Krasilnikov IV
Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851204
[TBL] [Abstract][Full Text] [Related]
20. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
